Naringenin Restores Osteogenic Differentiation in TNF-α-Treated Bone Marrow Mesenchymal Stem Cells by Targeting AKR1B1

In vitro experiments demonstrated that naringenin restored osteogenic capacity in TNF-α-treated human bone marrow MSCs, enhancing ALP activity, mineralization, and expression of RUNX2/OCN while reducing IL-6/IL-1β levels.